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A bs tr ac t
Background
Duplications and deletions in the human genome can cause disease or predispose 
persons to disease. Advances in technologies to detect these changes allow for the 
routine identification of submicroscopic imbalances in large numbers of patients.
Methods
We tested for the presence of microdeletions and microduplications at a specific 
region of chromosome 1q21.1 in two groups of patients with unexplained mental 
retardation, autism, or congenital anomalies and in unaffected persons.
Results
We identified 25 persons with a recurrent 1.35-Mb deletion within 1q21.1 from screen-
ing 5218 patients. The microdeletions had arisen de novo in eight patients, were inher-
ited from a mildly affected parent in three patients, were inherited from an apparently 
unaffected parent in six patients, and were of unknown inheritance in eight patients. 
The deletion was absent in a series of 4737 control persons (P = 1.1×10−7). We found 
considerable variability in the level of phenotypic expression of the microdeletion; phe-
notypes included mild-to-moderate mental retardation, microcephaly, cardiac abnor-
malities, and cataracts. The reciprocal duplication was enriched in nine children with 
mental retardation or autism spectrum disorder and other variable features (P = 0.02). 
We identified three deletions and three duplications of the 1q21.1 region in an indepen-
dent sample of 788 patients with mental retardation and congenital anomalies.
Conclusions
We have identified recurrent molecular lesions that elude syndromic classification 
and whose disease manifestations must be considered in a broader context of de-
velopment as opposed to being assigned to a specific disease. Clinical diagnosis in 
patients with these lesions may be most readily achieved on the basis of genotype 
rather than phenotype.
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R ecent advances in technologies such as comparative genomic hybridiza-tion (CGH; see Glossary) allow for the 
routine detection of submicroscopic deletions and 
duplications. Several studies of persons with men-
tal retardation or congenital anomalies of un-
known cause have led to the identification of new 
genomic disorders.1-10 Classically, criteria that 
have been applied to determine whether a given 
rearrangement is causative include de novo appear-
ance of the deletion or duplication in an affected 
individual (i.e., it is not present in unaffected par-
ents), recurrence of the same or an overlapping 
event in similarly affected persons, and absence 
of the deletion or duplication in a control popula-
tion. Examples of genomic disorders with these 
features include the Williams–Beuren syndrome, 
the 17q21.31 microdeletion syndrome, and the 
Prader–Willi and Angelman syndromes.
As more patients are identified with a given 
unbalanced microrearrangement, it has become 
clear that some genomic disorders have high pen-
etrance but a wide range of phenotypic severity. 
For example, although 90% of persons with the 
22q11 deletion syndrome have the same 3-Mb dele-
tion on chromosome 22, the phenotypic features 
are highly variable. Congenital heart disease is 
found in most (74%) but not all carriers of the 
deletion, and cleft palate is found in 27% of car-
riers (reviewed in Robin and Shprintzen11). More 
recently, reports of microdeletions or duplications 
with apparently incomplete penetrance and vari-
able expressivity have been identified in mental 
retardation–multiple congenital anomalies, autism, 
and other psychiatric disorders.12-16 The 1q21.1 
microdeletions associated with the thrombocy-
topenia–absent radius syndrome are necessary 
but not sufficient to cause disease.17 As these re-
ports accumulate, it is becoming clear that the 
phenotypes associated with imbalances of some 
regions of the genome can be variable, and modi-
fiers probably play an important role. The ascer-
tainment and description of patients with a spe-
cific chromosomal rearrangement critically affects 
the spectrum of phenotypes associated with it.
Me thods
Populations of Patients
DNA samples were obtained from the series de-
scribed in Tables 1A and 1B in the Supplemen-
tary Appendix (available with the full text of this 
article at www.nejm.org) after approval by local 
institutional review boards at each of the partici-
pating centers in Europe and the United States. 
Series 1 and 2, 4 through 11, 13 through 15, and 
the Dutch series of 788 patients came from diag-
nostic referral centers to which the majority of 
patients (95%) were referred for mental retarda-
tion with or without other features. Series 3 and 
12 comprise probands with a diagnosis of autism 
according to Autism Diagnostic Interview–Revised 
(ADI-R) and Autism Diagnostic Observation Sched-
ule (ADOS) criteria. Written informed consent was 
provided by all patients or, if children, by their 
parent or guardian. 
Determining Variation in Copy Number
Affected Persons
The method of screening for changes in copy 
number for each series is included in Table 1A in 
the Supplementary Appendix. The Dutch series 
of patients was screened using array-based CGH 
involving a bacterial artificial chromosome mi-
croarray, as described in Table 1B in the Supple-
mentary Appendix. Rearrangements of 1q21.1 
were further analyzed with the use of custom oli-
gonucleotide arrays (NimbleGen Systems). Details 
are given in the Methods section of the Supple-
mentary Appendix.18-20
Unaffected Persons
We evaluated 2063 unaffected persons, using 
HumanHap 300, HumanHap 550, or HumanHap 
650Y Genotyping BeadChips (Illumina) (Table 2 
Glossary 
Comparative genomic hybridization (CGH): An assay in 
which DNA samples from patients and from refer-
ence genomes are labeled with different fluorescent 
dyes and cohybridized to an array containing known 
DNA sequences. Differences in relative fluorescence 
intensities of hybridized DNA on the microarray re-
flect differences in copy number between the ge-
nome of the patients and reference DNA.
Nonallelic homologous recombination: Aberrant meiot-
ic recombination between nonallelic segmental du-
plications that are highly homologous but located at 
different places on the chromosome. This recombi-
nation causes duplication, deletion, or inversion of 
the sequence between the homologous blocks of DNA.
Segmental duplications: Large stretches of DNA (>1 kb 
in length), with more than 90% sequence identity, 
that are present at two or more places in the genome. 
These duplication blocks often include one or more 
genes and constitute approximately 5% of the human 
genome. They are also referred to as low-copy repeats 
or duplicons.
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in the Supplementary Appendix; 91, 206, or 212 
probes used, respectively, within the critical re-
gion). Hybridization, data analysis, and copy-
number analysis, with particular reference to 
chromosome 1q21.1 (mapping between genome 
coordinates 143,500,000 and 145,000,000 on chro-
mosome 1, according to National Center for Bio-
technology Information [NCBI] build 35), were 
performed according to published protocols.21 
We also evaluated 300 unaffected persons, using 
a quantitative real-time polymerase-chain-reac-
tion (PCR) assay for changes in copy number at 
five loci within the region of minimal deletion 
(primer list available on request). Details about 
this assay, as well as information about the Taq-
Man quantitative PCR, DNA-methylation studies, 
sequence analysis, and fluorescence in situ hybrid-
ization (FISH), are given in the Supplementary 
Appendix.
R esult s
Chromosome 1q21.1 Rearrangements  
in Affected Persons
We previously described one person with a dele-
tion of 1q21.1 and another with an overlapping 
duplication in a series of 390 persons screened by 
array-based CGH involving a bacterial artificial 
chromosome microarray.2,8 These persons had 
global delay, growth retardation, and seizures (Pa-
tient 1) (Table 1) and mental retardation, growth 
retardation, and facial dysmorphism (Patient 2) 
(Table 3 in the Supplementary Appendix). In a 
collaborative study of 3788 patients from 12 cen-
ters in Europe and the United States using array-
based CGH (Table 1A in the Supplementary Ap-
pendix), we identified an additional 22 probands 
with deletion and 8 probands with duplication. 
Targeted screening of another 1040 persons with 
unexplained mental retardation, by means of two 
TaqMan quantitative PCR assays within the com-
monly deleted region, resulted in detection of a 
deletion in two additional patients. Thus, from a 
total of 5218 persons with idiopathic mental re-
tardation, autism, or congenital anomalies, we 
have a series of 25 unrelated probands with over-
lapping deletions of 1q21.1 (0.5%) (Fig. 1A) and 
9 persons with the apparently reciprocal duplica-
tion (0.2%) (Fig. 1B). Five persons (four with a 
1q21.1 deletion and one with a duplication) also 
carried one or more additional chromosome ab-
normalities that could have contributed to their 
phenotype and were therefore excluded from fur-
ther analysis (see Table 4 in the Supplementary 
Appendix for their phenotypic features).
The minimally deleted region spans approxi-
mately 1.35 Mb (on chromosome 1, 143.65 to 145 
Mb [according to NCBI build 35], or 145 to 146.35 
Mb [according to NCBI build 36]) and includes at 
least seven genes. The majority of persons stud-
ied have deletions with breakpoints (BP) in seg-
mental-duplication blocks BP3 and BP4 (see Glos-
sary and Fig. 1). Patient 12 has a larger, atypical 
deletion approximately 5.5 Mb in size that extends 
more proximally toward the centromere than the 
common deletion (on chromosome 1, 142.5 to 
148.0 Mb [NCBI build 36]) (Fig. 1 in the Supple-
mentary Appendix). Of the 21 probands without 
secondary karyotype abnormalities, the 1q21.1 
deletion was de novo in 7 (3 with maternal origin, 
1 with paternal origin, and 3 with undetermined 
parental origin), maternally inherited in 3, pater-
nally inherited in 4, and of unknown inheritance 
(parents unavailable for study) in 7 (Table 1).
The phenotypes of persons with 1q21.1 dele-
tions are described in Table 1 (21 patients with-
out additional chromosomal abnormalities) and 
Table 4 in the Supplementary Appendix (4 patients 
with additional chromosomal abnormalities). Ped-
igrees of eight probands are shown in Figure 2. 
The majority of persons with a deletion have a 
history of mild-to-moderate developmental delay 
(16 of 21 [76.2%]) and dysmorphic features (17 of 
21 [81.0%]), consistent with their ascertainment 
criteria. Three parents are also mildly affected; 
however, five probands had normal cognitive de-
velopment, and four apparently unaffected par-
ents have the same deletion. In addition, 14 of the 
21 patients (66.7%) and 2 parents with the dele-
tion have microcephaly or relative microcephaly. 
Other phenotypic features noted in more than 
one patient with the deletion include ligamentous 
laxity or joint hypermobility (five patients), con-
genital heart abnormality (six patients), hypoto-
nia (five patients), seizures (three patients) and 
cataracts (three patients). There are no notable 
phenotypic differences among carriers of a dele-
tion with different breakpoints. Consistent with 
variability of phenotypic outcome, we noted that 
the same region was recently described in an 
adult patient with schizophrenia22 (Table 4 in 
the Supplementary Appendix). We obtained DNA 
from this patient to map the breakpoints; our 
results show that the deletion in this patient 
with adult-onset schizophrenia is apparently iden-
tical to the common 1.35-Mb deletion found in 
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our sample of patients with primarily childhood-
onset phenotypes (Fig. 3).
We also detected the reciprocal 1q21.1 dupli-
cation in nine persons (Fig. 1B), one of whom 
carried an additional large chromosomal abnor-
mality and was thus excluded from further analy-
sis (Table 4 in the Supplementary Appendix). Of 
the remaining eight patients with duplication, two 
had inheritance from an unaffected father, two 
had de novo duplication (parent of origin not 
known), and four did not have parental DNA 
available for analysis. Four of the eight patients 
with duplication (50.0%) had autism or autistic 
behaviors (Table 3 in the Supplementary Ap-
pendix). Other common phenotypic features of 
the eight duplication carriers include mild-to-
moderate mental retardation (in five [62.5%]), 
macrocephaly or relative macrocephaly (in four 
[50.0%]), and mild dysmorphic features (in five 
[62.5%]).
In an independent sample of 788 patients with 
mental retardation and congenital anomalies from 
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Figure 1 (following pages). High-Density Oligonucle-
otide-Array Mapping of Chromosome 1q21.1 Re-
arrangements in the Study Patients.
Sixteen 1q21.1 deletions (Panel A) and seven 1q21.1 
duplications (Panel B) from patients without other 
chromosomal abnormalities were identified on chro-
mosome 1q21.1. The region of minimal rearrange-
ment is located from approximately 143,650,000 to 
145,000,000 bp (pink shading) and contains two as-
sembly gaps and eight genes in the National Center 
for Biotechnology Information Reference Sequence 
(RefSeq) collection. In Panel B, a patient with a mi-
crodeletion (Patient 1) is shown for comparison with 
the duplication carriers (Patients 1 through 7 shown). 
Segmental-duplication blocks are shown, with the ap-
proximate breakpoint (BP) regions indicated with 
green shading. The microdeletion associated with the 
thrombocytopenia-absent radius (TAR) syndrome17 is 
shaded in blue. For each patient, deviations from 0 of 
probe log2 ratios are depicted by vertical bars, with 
those exceeding a threshold of 1.5 SD from the mean 
probe ratio shown in green or red to represent relative 
gains or losses, respectively; bars below this threshold 
are black (gains) or gray (losses). Segmental duplica-
tions of increasing similarity are also shown, as hori-
zontal bars highlighted with green shading: 90 to 98% 
(gray bars), >98 to 99% (yellow bars), and >99% (or-
ange bars). Results for Patients 17 through 20 with de-
letions and Patient 8 with a duplication are shown in 
Figure 3 in the Supplementary Appendix. Patient 21 
with a deletion and Patient 6 with a duplication were 
evaluated only by means of the screening platform 
listed in Table 1A in the Supplementary Appendix, be-
cause of insufficient DNA for additional oligonucle-
otide-array analysis (data not shown).
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the Netherlands, we identified deletion in 3 pa-
tients (0.4%) and duplication in another 3 patients 
(0.4%). The phenotypic features and inheritance 
patterns of these patients are listed in Table 1B 
in the Supplementary Appendix.
Deletions and Duplications  
in Unaffected Persons
To assess the frequency of 1q21.1 rearrangements 
in the general population, we evaluated data on 
copy number from three control populations: 
2063 persons evaluated by means of single-nucle-
otide polymorphism (SNP)–genotyping bead ar-
rays21 (Itsara A: personal communication), 300 
persons evaluated by means of quantitative PCR 
performed on specimens from five different lo-
cations within the minimal-deletion region, and 
2374 persons from previously published studies 
for which the copy-number variation of the 1q21.1 
region was genotyped (Table 2 in the Supplemen-
tary Appendix).18,20,23-29 In this series of 4737 
controls, we found no deletions of the 1q21.1 
minimal-deletion region. Two controls each had 
one small duplication (117 kb and 184 kb) at the 
distal end of the minimal-deletion region, and 
only one control had confirmed duplication of the 
entire minimal 1q21.1 rearrangement region29 
(Feuk L: personal communication). Thus, the fre-
quency of the 1.35-Mb deletion is clearly enriched 
in affected persons as compared with controls 
(25 of 5218 patients vs. 0 of 4737 controls, 
P = 1.1×10−7 by Fisher’s exact test). Although de-
tected at a lower frequency in our series, the recip-
rocal duplication also appears to be enriched in 
affected persons (9 of 5218 patients, vs. 1 of 4737 
controls; P = 0.02 by Fisher’s exact test).
Genomic Structure of the 1q21.1 Region
The genomic structure of the 1q21.1 breakpoint 
regions is extremely complex, with at least four 
large segmental-duplication blocks ranging in size 
from 270 kb to 2.2 Mb (Fig. 1, and Fig. 1 in the 
Supplementary Appendix), most of which exhibit 
copy-number polymorphism in the general pop-
ulation25,27 (see also the Database of Genomic 
Variants, http://projects.tcag.ca/variation/). A large 
inversion polymorphism that spans the recurrent 
deletion–duplication region, a feature associated 
with many other recurrent genomic disorders, 
has also been described.27,30 The complexity of 
1q21.1 is underscored by the fact that there are 
still 15 assembly gaps, representing approximately 
700 kb of missing sequence, in the most recent 
NCBI genome build (build 36). Of the 5.4 Mb of 
sequence within 1q21.1, only 25% represents 
unique (i.e., nonduplicated) sequence.
Although the complexity of the region com-
plicates mapping efforts, our high-density array-
based CGH results show that the proximal and 
distal breakpoints of the deletion–duplication 
events map within large segmental-duplication 
blocks. Our analysis reveals four possible break-
33p9
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point regions, BP1 and BP4 (Fig. 1, and Fig. 1 in 
the Supplementary Appendix), as well as BP2 and 
BP3, which correspond to the previously described 
breakpoints associated with the thrombocytope-
nia–absent radius syndrome.17 Breakpoints of the 
most common 1.35-Mb deletion map to BP3 and 
BP4, which share 281 kb of sequence with more 
than 99.9% identity (Table 5 in the Supplemen-
tary Appendix). The structure of the 1q21.1 region 
(with multiple large blocks of highly homologous 
segmental duplication), the frequency of recur-
rent deletions or duplications, and the additional 
observation of reciprocal deletion and duplication 
events strongly suggest nonallelic homologous re-
combination as the mechanism that generates the 
deletion and duplication.
The presence of numerous assembly gaps in 
the 1q21.1 region hinders precise mapping of the 
chromosomal breakpoints that flank each dupli-
cation or deletion. Moreover, these gaps may con-
tain genes that are absent from the current refer-
ence sequence and could potentially contribute 
to phenotypic differences between deletion car-
riers. One example is a partially duplicated copy 
of the hydrocephalus-inducing homologue (mouse) 
2 gene HYDIN2, recently mapped to 1q21.1.31 We 
confirmed the presence of a HYDIN homologue 
within 1q21.1 by using FISH analysis involving 
two chromosome 16q22 fosmids containing the 
chromosome-16 HYDIN sequence (Fig. 2 in the 
Supplementary Appendix). Analysis of two dele-
tion carriers (Patient 7 and her unaffected moth-
er) revealed that the HYDIN2 locus lies within the 
commonly deleted region and therefore may re-
side in one of the gaps between BP3 and BP4. 
Because probes designed to detect HYDIN also 
hybridize with HYDIN2 sequence, data obtained 
through CGH studies, involving a whole-genome 
array, of persons with the 1q21.1 deletion sug-
gest the existence of an approximately 35-kb dele-
tion at 16q22 (Fig. 2 in the Supplementary Ap-
pendix) — that is, a false positive for the 16q22 
deletion. FISH studies revealed only the 1q21.1 
deletion and did not confirm the apparent 
16q22 deletion.
Analysis of Potential Modifiers of Phenotype
Given associations between GJA5 (the gene encod-
ing connexin 40) and cardiac phenotypes32-35 and 
between GJA8 (the gene encoding connexin 50) 
and eye phenotypes,36-38 we hypothesized that 
coding variants on the remaining GJA5 or GJA8 
allele of deletion carriers may contribute to the 
cardiac or eye phenotypes, respectively, seen in 
some patients. However, we sequenced the cod-
ing and upstream regions of both genes in 11 
deletion carriers and found no mutations (Table 
6 in the Supplementary Appendix). We also inves-
tigated the possibility that epigenetic differences 
on the single remaining 1q21.1 allele might un-
derlie the variable phenotype of those with 1q21.1 
deletions. We analyzed the CpG (cytidine–phos-
phate–guanosine) methylation status within the 
deletion region in an affected 1q21.1 deletion car-
rier (Patient 7) and in her mother, who also carries 
the deletion but is unaffected. We found no signifi-
cant differences between them (data not shown).
Discussion
Our data show that 1q21.1 deletions are associ-
ated with a broad array of pediatric developmen-
tal abnormalities. There is considerable pheno-
typic diversity associated with haploinsufficiency 
of 1q21.1, consistent with previous reports of ap-
parently identical 1q21.1 deletions in patients 
with different phenotypes, including isolated heart 
defects,39 cataracts,27 mullerian aplasia,40 autism,41 
and schizophrenia.13,14,22 We identified several 
unaffected deletion carriers; however, it is pos-
sible that apparently unaffected parents who have 
a 1q21.1 deletion could also have subtle pheno-
typic features consistent with the deletion that 
would become evident on further clinical evalua-
tion. In one of our patients (Patient 2), for exam-
ple, subtle cataracts and a patent ductus arterio-
sus were detected only after directed studies were 
performed after discovery of the 1q21 deletion 
(Table 1).
The reciprocal duplication was detected less 
frequently in our series, a finding that is consis-
tent with recent studies showing that rates of dele-
tion mediated by nonallelic homologous recom-
bination are higher than that for duplications in 
the male germ line.42 Nonetheless, the duplica-
tion is also enriched in affected persons as com-
pared with controls (P = 0.02). Seven of the eight 
duplication carriers have learning or developmen-
tal delay or mental retardation. Four of the eight 
duplication carriers have autistic behaviors or 
autism, consistent with previously reported 1q21.1 
duplications in patients with autism.41 Two pa-
tients were initially identified among 141 patients 
with autism, a finding that suggests even greater 
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enrichment in this population (vs. 1 of 4737 con-
trols, P = 0.002 by Fisher’s exact test). Other phe-
notypes described in the majority of patients for 
whom data are available include macrocephaly 
or relative macrocephaly. However, because of the 
small number of patients with a duplication event 
in our series, identification of additional carriers 
will be required to determine whether these clini-
cal manifestations are consistent with the pres-
ence of the duplication.
Several possibilities may account for the phe-
notypic variability we found among carriers of 
1q21.1 rearrangements, including variation in ge-
netic background, epigenetic phenomena such as 
imprinting, expression or regulatory variation 
among genes in the rearrangement region, and 
(in the case of deletions) the unmasking of re-
cessive variants residing on the single remaining 
allele. It is known, for example, that coding vari-
ants on the nondeleted allele in carriers of the 
velocardiofacial syndrome deletion can modify the 
phenotypes of patients.43,44 Sequence analysis of 
GJA5 and GJA8 (the genes previously implicated 
in cardiac and eye phenotypes, respectively) in 
11 deletion carriers yielded no data to support 
the unmasking of recessive variants as a cause of 
phenotypic variability. Likewise, preliminary data 
from methylation analyses of an affected dele-
tion carrier and her mother, who also carried the 
deletion but was unaffected, suggest that differ-
ences in the methylation status of the nondeleted 
1q21.1 locus does not contribute to the variabil-
ity in phenotype. Finally, parent-of-origin studies 
reveal both maternal and paternal transmission 
of the deletion, making it unlikely that imprint-
ing plays a role in phenotypic variability.
Our results emphasize the importance of rare 
structural variants in human disease; they also 
demonstrate some of the challenges. First, large 
samples of patients and controls are required to 
show that a specific variant is pathogenic. Al-
though there have been several reports of patients 
with 1q21.1 deletions in studies of specific dis-
eases,22,39-41 our study shows that recurrent 1q21.1 
microdeletions are significantly associated with 
pediatric disease, through systematic comparison 
of the frequency of rearrangements in affected 
and unaffected persons. Second, detailed clinical 
evaluations of affected persons disclosed a much 
broader spectrum of phenotypes than anticipat-
ed, dispelling any notion of syndromic disease. 
While this article was being reviewed before pub-
lication, two groups reported enrichment of 1q21.1 
deletions in persons with schizophrenia13,14; they 
report deletions in 0.26% of patients with schizo-
phrenia, as compared with our finding of dele-
tions in 0.5% of persons with developmental ab-
normalities. These results confirm the association 
of 1q21.1 rearrangements with a broad spectrum 
of phenotypes but also further dispel the notion 
that rare copy-number variants will necessarily 
follow the one gene (or one rearrangement)–one 
disease model.
The phenotypic diversity, incomplete pene-
trance, and lack of distinct syndromic features 
associated with 1q21 rearrangements will com-
plicate genetic diagnosis and counseling. For cli-
nicians caring for patients with developmental 
abnormalities, the identification of a 1q21 re-
arrangement by means of diagnostic array-based 
CGH should be considered a clinically significant 
finding and probably an influential genetic factor 
contributing to the phenotype. Evaluation of 
family members may reveal apparently unaf-
fected (or mildly affected) persons carrying the 
same rearrangement. Given the spectrum of pos-
sible outcomes associated with 1q21 rearrange-
ments, such persons should be monitored in the 
long term for learning disabilities, autism, or 
schizophrenia or other neuropsychiatric disor-
ders. Counseling in the prenatal setting will pre-
sent the greatest challenge: although the likeli-
hood of an abnormal outcome is high in a person 
with a 1q21.1 rearrangement, current knowledge 
does not allow us to predict which abnormalities 
will occur in any given person. Further investi-
gation of genetic and environmental modifiers 
may explain such variable expressivity but requires 
characterization of an even larger number of pa-
tients with a 1q21 deletion. Data on rare, de novo 
structural variants are collectively beginning to 
explain an increasingly greater fraction (approxi-
mately 15%) of patients with developmental de-
lay, autism, schizophrenia, or other neuropsy-
chiatric disorders, and our study adds 1q21.1 as 
a locus to include in screening panels for such 
patients.
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